Impact of Definitive Drug–Drug Interaction Testing on Medication Management and Patient Care

Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–70. https://doi.org/10.1177/0091270007312153 .

US Food and Drug Administration. Drug development and drug interactions. 2018. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm080499.htm#overview . Accessed 24 Sep 2018.

Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66. https://doi.org/10.1001/jama.296.15.1858 .

Taylor R Jr, V Pergolizzi J Jr, Puenpatom RA, Summers KH. Economic implications of potential drug–drug interactions in chronic pain patients. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):725–34. https://doi.org/10.1586/14737167.2013.851006 .

Moura CS, Acurcio FA, Belo NO. Drug–drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266–72.

Hug BL, Keohane C, Seger DL, Yoon C, Bates DW. The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf. 2012;38(3):120–6.

US Food and Drug Administration. Preventable adverse drug reactions: a focus on drug interactions. 2018. https://www.fda.gov/Drugs/Developmentapprovalprocess/Developmentresources/Druginteractionslabeling/ucm110632.htm . Accessed 24 Sep 2018.

Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–53. https://doi.org/10.1007/s40264-015-0281-0 .

Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol. 2009;9:8. https://doi.org/10.1186/1472-6904-9-8 .

Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–9. https://doi.org/10.1001/jama.294.10.1255 .

Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol. 2015;80(4):818–26. https://doi.org/10.1111/bcp.12567 .

Veeren J, Weiss M. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008–2015. J Pharm Health Serv Res. 2017;8:5–11.

Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681–95. https://doi.org/10.1080/14740338.2018.1491547 .

Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl. 1):S73–7. https://doi.org/10.4103/0976-500X.120957 .

Pergolizzi JV Jr, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, et al. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Spec Pharm. 2014;20(5):467–76. https://doi.org/10.18553/jmcp.2014.20.5.467 .

Adverse drug reactions and drug-drug interactions: consequences and costs. American Forensic Medical Specialists. 2018. https://www.amfs.com/news/articles-from-our-experts/adverse-drug-reactions-and-drug-drug-interactions-consequences-and-costs/ . Accessed 27 Jun 2018.

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prev Study Group. JAMA. 1995;274(1):29–34.

Wright A, Feblowitz J, Phansalkar S, Liu J, Wilcox A, Keohane C, et al. Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. Am J Health Syst Pharm. 2012;69(3):221–7. https://doi.org/10.2146/ajhp110084 .

Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83–94. https://doi.org/10.1517/14740338.2012.631910 .

Comer D, Couto J, Aguiar R, Wu P, Elliott DJ. Usefulness of pharmacy claims for medication reconciliation in primary care. Am J Manag Care. 2015;21(7):486–93.

Gleason KM, McDaniel MR, Feinglass J, Baker DW, Lindquist L, Liss D, et al. Results of the Medications at Transitions and Clinical Handoffs (MATCH) study: an analysis of medication reconciliation errors and risk factors at hospital admission. J Gen Intern Med. 2010;25(5):441–7. https://doi.org/10.1007/s11606-010-1256-6 .

Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78. https://doi.org/10.1001/jama.2008.892 .

Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–82. https://doi.org/10.1001/jamainternmed.2015.8581 .

Cars T, Wettermark B, Malmstrom RE, Ekeving G, Vikstrom B, Bergman U, et al. Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model. Basic Clin Pharmacol Toxicol. 2013;112(6):392–400. https://doi.org/10.1111/bcpt.12055 .

Nanji KC, Slight SP, Seger DL, Cho I, Fiskio JM, Redden LM, et al. Overrides of medication-related clinical decision support alerts in outpatients. J Am Med Inform Assoc. 2014;21(3):487–91. https://doi.org/10.1136/amiajnl-2013-001813 .

Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(Suppl. 11):S276–87.

Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27(12):1021–48. https://doi.org/10.1007/s40263-013-0114-6 .

Spina E, Trifiro G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67. https://doi.org/10.2165/11594710-000000000-00000 .

Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opin Drug Metab Toxicol. 2013;9(6):675–97. https://doi.org/10.1517/17425255.2013.783567 .

Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73(6):1484–90. https://doi.org/10.1097/TA.0b013e318267cd80 .

Pergolizzi JV Jr, Labhsetwar SA, Amy Puenpatom R, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract. 2012;12(1):45–56. https://doi.org/10.1111/j.1533-2500.2011.00503.x .

Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the “Fifth Vital Sign” era: historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend. 2017;173(Suppl. 1):S11–21. https://doi.org/10.1016/j.drugalcdep.2016.12.002 .

Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–97. https://doi.org/10.1002/pds.3592 .

Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25. https://doi.org/10.1001/jama.2016.16201 .

Ernst FR, Mills JR, Berner T, House J, Herndon C. Opioid medication practices observed in chronic pain patients presenting for all-causes to emergency departments: prevalence and impact on health care outcomes. J Manag Care Spec Pharm. 2015;21(10):925–36. https://doi.org/10.18553/jmcp.2015.21.10.925 .